Hereditary Genetic Testing Market Research Reveals Path To $40.12 Billion By 2030

The hereditary genetic testing market is rapidly evolving as more individuals and healthcare providers recognize the value of genetic insights for disease prevention and personalized treatment. With continuous technological advancements and increasing integration into healthcare systems, this sector is set for substantial growth in the coming years. Below is a detailed overview of the market size, key players, emerging trends, and segmentation.

Projected Growth and Market Size of the Hereditary Genetic Testing Market
The hereditary genetic testing market is anticipated to expand significantly by 2030, reaching a valuation of $40.12 billion. This growth represents a compound annual growth rate (CAGR) of 10.9%. Drivers behind this expansion include breakthroughs in next-generation sequencing technologies, heightened interest in personalized medicine, broader applications in pharmacogenomics, increased healthcare investments in preventive care, and the growing incorporation of genetic counseling services. Key trends shaping the market forecast include a surge in preventive and predictive genetic testing, rising demand for early cancer risk evaluations, expansion of direct-to-consumer testing options, increased prenatal and newborn screening, as well as greater awareness of inherited cardiovascular and rare diseases.

Download a free sample of the hereditary genetic testing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20559&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Prominent Players Defining the Hereditary Genetic Testing Market
The market features several influential companies that are shaping the direction of hereditary genetic testing. Leading organizations include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Hologic Inc., Exact Sciences Corporation, Fulgent Genetics Inc., BioReference Laboratories Inc., BGI Group, Invitae Corporation, Color Health Inc., MedGenome Inc., Devyser AB, Mapmygenome India Ltd., Igenomix S.L.P., Myriad Genetics Inc., Natera Inc., Ambry Genetics Corporation, GeneDx LLC, Centogene N.V., CooperSurgical Inc., and Sema4.

Strategic Moves in the Industry Highlighted by Recent Acquisition
In August 2024, Laboratory Corporation of America Holdings (Labcorp), a prominent US-based laboratory services provider, acquired select assets from Invitae Corporation, although the financial details remain undisclosed. This acquisition is aimed at strengthening Labcorp's specialty testing portfolio and leveraging genetic data to improve clinical trials and treatment plans, particularly in oncology and certain rare diseases. Invitae Corporation is well-known for its genetic testing services targeting oncology and rare disease diagnostics.

View the full hereditary genetic testing market report:
https://www.thebusinessresearchcompany.com/report/hereditary-genetic-testing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Emerging Trends Shaping the Future of Hereditary Genetic Testing
Market leaders are focusing on developing sophisticated genomic tools, such as multi-cancer multigene panels, designed to enhance early cancer detection and enable more precise, personalized treatments. These panels analyze multiple genes simultaneously to identify mutations related to various cancers, facilitating timely intervention. For example, in February 2024, Exact Sciences Corporation released the Riskguard hereditary cancer test in the United States. This test provides a detailed, personalized report on gene-specific and familial cancer risks for 10 common cancer types, using a simple blood or saliva sample. It assists patients in understanding their risk, informs screening and therapeutic decisions, and helps stratify risk for individuals with a family history by detecting actionable gene variants.

Detailed Segmentation of the Hereditary Genetic Testing Market
The hereditary genetic testing market is categorized comprehensively to cover various dimensions:

1) By Type:
- Predictive and Presymptomatic Testing
- Carrier Testing
- Prenatal and Newborn Testing
- Diagnostic Testing
- Pharmacogenomic Testing
- Other Types

2) By Technology:
- Cytogenetic Testing
- Biochemical Testing
- Molecular Testing

3) By Clinical Application:
- Cancer Genetic Testing
- Cardiovascular Genetic Testing
- Neurological Genetic Testing
- Rare Diseases Genetic Testing

4) By End User:
- Hospitals and Clinics
- Diagnostic Laboratories
- Research Institutes
- Direct-to-Consumer (DTC) Genetic Testing Companies

Further, subcategories within these segments include:

- Predictive and Presymptomatic Testing: Disease risk prediction, inherited cancer risk testing, cardiovascular disease risk evaluation, neurodegenerative disease risk testing.
- Carrier Testing: Screening for inherited genetic disorders, autosomal recessive disease carrier status, inherited condition carrier identification.
- Prenatal and Newborn Testing: Non-invasive prenatal testing (NIPT), amniocentesis and chorionic villus sampling (CVS), newborn screening for genetic disorders, preconception genetic screening.
- Diagnostic Testing: Confirmatory genetic testing for suspected disorders, inherited syndromes and congenital disease testing, cancer and tumor profiling.
- Pharmacogenomic Testing: Drug response and efficacy testing, drug sensitivity and side effect screening, personalized medicine optimization.
- Other Types: Genetic testing for wellness and lifestyle, ancestry and genealogy testing, research-focused genetic testing.

This structured segmentation provides a clear perspective on the extensive scope of hereditary genetic testing and the various avenues through which it is delivered and applied across healthcare.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.